Clinical Trial

HH-120 Nasal Spray for Post-exposure Prevention of SARS-CoV-2

Enrolling by Invitation Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated October 10, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study will assess the efficacy of HH-120 nasal spray in participants for the post-exposure prevention of SARS-CoV-2.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-03-27; most recent amendment 2024-10-08.
Status change: Recruiting → Enrolling by Invitation 2024-10-08
Status change: Not Yet Recruiting → Recruiting 2023-09-27
Trial Details
NCT Number NCT05787418
Lead Sponsor Huahui Health
Conditions COVID-19
Enrollment 1,200 participants
Start Date 2023-03-31
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-04-01 (estimated)
Updated on ClinicalTrials.gov 2024-10-10